The global market for smoking cessation and nicotine de-addiction products is expected to grow at a CAGR of 15% during the forecast period of 2022 to 2030, according to a report from Research & Markets.
One of the primary causes that are contributing to the expansion of the smoking cessation and nicotine de-addiction industry is the growing number of people all over the world who are attempting to give up smoking. Because of the harmful effects that nicotine and cigarette addiction have on the cardiovascular and respiratory systems, the government is placing a greater emphasis on the enforcement of stringent rules.
The World Health Organization (WHO) estimates that tobacco use is responsible for the deaths of more than 8 million people annually. More than 7 million of these deaths are directly attributable to the use of tobacco products, whereas around 1.2 million are attributable to the exposure of non-smokers to second-hand smoke. 8% of the world's 1.3 billion people who use tobacco live in low- or middle-income nations, which have the highest rates of disease and death caused by tobacco use.
In the year 2021, 65.3% of young people (students in middle and high school) who used smoking cessation medicine or products were seriously considering giving up the use of all tobacco products. Products that help people quit smoking are an effective form of treatment for people who are addicted to tobacco and cigarettes.
Warning labels on cigarette packages must now include the phrase "Smoking is harmful to your health," and some nations have even resorted to using graphic images of people who have been harmed by smoking in order to get the message through. On the other hand, this has not exactly been a game-changer in terms of getting people to give up smoking. However, there have been considerable initiatives to quit smoking among the community of smokers because nongovernmental groups and international healthcare organizations have raised awareness about the dangers of smoking. Additionally, the introduction of smoking cessation therapies by various companies has resulted in the growth of a wide variety of alternative therapies in the global smoking cessation and nicotine de-addiction products market. In point of fact, addiction to nicotine is a significant component that contributes to increased sales of cigarettes. As a result, there is a growing demand in the market for nicotine detoxification products such as gums and patches that contain nicotine.
Nicotine replacement therapies (also known as NRTs) were the first products for smoking cessation treatment to be licensed by the Food and Drug Administration (FDA) in the United States. Both Buproprion (brand name Zyban) and Varenicline (brand name Chantix) are non-nicotine treatments for smoking cessation that have been approved by the FDA in the United States.